Atlanta—A new vaccine promises to decrease the number of difficult-to-treat nosocomial infections by boosting immunity against Staphylococcus aureus, a common cause of hospital-related infections. Called StaphVax, the vaccine reduced infection rates by 57% in a high-risk population for as long as 10 months, reported Gary Horwith, MD, at a meeting last month of the Advisory Committee on Immunization Practices (ACIP). The ACIP advises the Centers for Disease Control and Prevention. Horwith is vice president for clinical research of Nabi Inc, the Boca Raton, Fla, drug firm that developed StaphVax.
Vastag B. New Vaccine Decreases Rate of Nosocomial Infections. JAMA. 2001;285(12):1565-1566. doi:10.1001/jama.285.12.1565-JMN0328-3-1